| Information | |
|---|---|
| has gloss | eng: SB-649,868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573. |
| lexicalization | eng: SB-649,868 |
| lexicalization | eng: SB649868 |
| instance of | (noun) a drug that reduces excitability and calms a person downer, sedative, sedative drug, depressant |
Lexvo © 2008-2025 Gerard de Melo. Contact Legal Information / Imprint